Egypt’s Ministry of Education and Scientific Research signed on Sunday an agreement with the Ministry of Agriculture and private company Eva Pharma to pursue studies to produce the country’s second domestically manufactured COVID-19 vaccine, the ministry said in a statement on Monday.
CEO of Eva Pharma Riad Armanious has said that the ministries of higher education and agriculture will work on producing the viral antigen for the vaccine, which will be manufactured at Eva Pharma industrial complex in accordance with the standards of the Egyptian Drug Authority (EDA), the World Health Organisation, and the US Food and Drug Administration.
Minister of Higher Education and acting Health Minister Hossam Abdel-Ghaffar, who attended the signing, has said in media statements that the vaccine will be manufactured after successfully undergoing clinical trials.
EgyVax is the second COVID-19 vaccine to be produced locally in Egypt after the COVI-VAX vaccine.
Last November, Minister Abdel-Ghaffar announced that the clinical trials for the COVI-VAX vaccine had kicked off and would conclude in six to nine months.
COVI-VAX is the result of a cooperation agreement between Egypt’s National Centre for Research (NCR) and the private sector bio-technology company Vaccine Valley.
In June, the COVI-VAX vaccine received the approval of the EDA to finish pre-clinical studies, 18 months after the NCR-affiliated Scientific Excellence Centre for Virology had launched a set of studies on the pandemic.
Egypt currently depends on imported COVID-19 vaccines.
Egypt has a stock of imported doses of the Sinopharm, Sinovac, AstraZeneca, Sputnik V, Moderna, Pfizer, and Johnson & Johnson vaccines.